Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
EA2192 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Thistrial is available at multiple Sutter locations. Please contact one of thefollowing about the study:
Site Point of Contacts
Alta Bates (CA164)
Painte’ Berniard Piante.Berniard@sutterhealth.org
California Pacific Medical Center (CA222)
Sophia Vu (Manager) Sophia.Vue@sutterhealth.org
Eden Medical Center (CA200)
Leah Galvez Leah.Galvez@sutterhealth.org
Mills Health Center (CA209)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
Memorial Medical Center (CA182)
Kristen Moorman Kristen.Moorman@sutterhealth.org
Palo Alto Medical Foundation (PAMF – All sites)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
SIMR Sutter Institute for Medical Research (SIMR – All sites)
Kirsten Babski Kirsten.Babski@sutterhealth.org
Sutter Cancer Research Consortium
NCIClinicalTrials@sutterhealth.org